Navigation Links
Study: Surefire Medical's Technology Improves Delivery Of Embolics In Cancer Treatment

WESTMINSTER, Colo., March 6, 2013 /PRNewswire/ -- Surefire Medical's new infusion system maximizes delivery of drugs directly to the tumor site while minimizing potential damage to non-target organs, according to a new study.  The ability to more safely and efficiently deliver embolic agents to target tumors locally marks a significant advance in radiation oncology procedures and in the treatment of liver cancer.

The 29 procedure study, led by Steven Rose , M.D. of the University of California at San Diego Medical Center (UCSD) and reported in CardioVascular and Interventional Radiology, determined that when the unique Surefire expandable anti-reflux tip is deployed, an approximate 20 mm Hg pressure drop occurs downstream from the tip, causing a reversal of blood flow in arteries between the liver and adjacent organs.  This phenomenon prevents the chemoembolization or radioembolization agents from flowing into downstream non-target vessels. 

"These results show that the new catheter technology makes it possible to prevent embolics from traveling to distal non-target vessels," said Rose. "We may potentially see improved patient outcomes because all blood flow carrying the embolics is directed to the liver while protecting the rest of the body."

The Surefire catheter's unique expandable tip also enables more of the embolic agents to reach their intended destination.

"Dr. Rose has identified a unique property of the Surefire Infusion System that is not available with standard end-hole catheters," said Aravind Arepally , M.D., Surefire Medical's Chief Scientific Officer.  "This should provide additional arsenal for doctors performing liver directed therapies."

According to Rose, the Surefire Infusion System provides both upstream and downstream protection.

"We are extremely pleased that the growing body of clinical evidence, coupled with the enthusiasm of our increasing user base at hospitals worldwide, continues to prove the efficacy of the Surefire line of catheters," said Surefire Medical CEO Jim Chomas .

About Surefire Medical

Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets.  Surefire's infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue.  For more information, please visit


SOURCE Surefire Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month
2. Inaugural Harris Poll Physician Pulse(SM) Study: Viagra® and Cialis® are Highest Ranked in Trust
3. Clinical Study: Dietary Supplement SagaPro Reduces Frequent Urination
4. WebMD Study: U.S. Doctors Deeply Divided on Many Matters of Ethical Ambiguity
5. Prostate Cancer Study: Most Patients Report Satisfaction After Robotic Surgery
6. Surefire Medical Receives FDA Clearance For High-Flow Microcatheter
7. Surefire Medicals Infusion System For Embolization Procedures Receives CE Mark Approval
8. Christopher Mennone Joins Surefire Medical Team As International Business Director
9. Surefire Medical, Inc.: Gene McGrevin Joins Surefire Medicals Board of Directors
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. Fujitsu to Showcase Radiation-Hardened RFID Using FRAM Technology at Interphex 2012 in New York City, Booth #2430
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
Breaking Medicine News(10 mins):